Diagnosis of Multiple Sclerosis: Progress and Challenges
Lancet 389:1336-1346, Brownlee, W.J.,et al, 2017
Multiple Sclerosis
NEJM 343:938-952, Noseworthy,J.H. et al, 2000
Multiple Sclerosis
Lancet 372:1502-1517, Compston,A. &Coles,A., 2008
Clinical Characteristics of African Americans vs Caucasian Americans with Multiple Sclerosis
Neurol 63:2039-2045, Bree,B.A.C.,et al, 2004
Antimyelin Antibodies as a Predictor of Clinically Definite Multiple Sclerosis After a First Demyelinating Event
NEJM 349:139-145,107, Berger,T.,et al, 2003
Early Onset Multiple Sclerosis
Neurol 59:1006-1010, Boiko,A.,et al, 2002
Progressive Forms of MS:Classification Streamlined or Consensus Overturned?
Lancet 355:162-163, Weinshenker,B.G., 2000
Diagnostic Criteria for Primary Progressive Multiple Sclerosis: A Position Paper
Ann Neurol 47:831-835, Thompson,A.J.,et al, 2000
Relapses and Progression of Disability in Multiple Sclerosis
NEJM 343:1430-1438,1486, Confavreux,C.,et al, 2000
Multiple Sclerosis That is Progressive From the Time of Onset, Clinical Characteristics and Progression of Disability
Arch Neurol 56:1138-1142, Andersson,P.B.,et al, 1999
Population Based Cost Utility Study of Interferon Beta-1b in Secondary Progressive Multiple Sclerosis
BMJ 319:1529-1533, Forbes,R.B.,et al, 1999
Interferon B Therapy for Multiple Sclerosis
Lancet 352:1486-1487, Goodkin,D.E., 1998